BACKGROUND
Neurofilament light chain (NfL) is an established biomarker for amyotrophic lateral sclerosis (ALS). However, it remains unclear whether biomarkers reflecting amyloid-β metabolism (Aβ), tau (phosphorylated tau, pTau), and astrogliosis (glial fibrillary acidic protein, GFAP) can complement NfL in clinical app...
Kazuki Obara, S. Janelidze, Daisuke Ito et al.· EBioMedicine· 0 citations
It is shown that functional connectivity changes associated with aging and AD are strongly aligned with separate fundamental axes of hierarchical brain communication, which suggest that both AD and aging alter major but orthogonal functional pathways in the brain.
Jonathan Ö. Rittmo, N. Franzmeier, O. Strandberg et al.· Nature Neuroscience· 0 citations
This multicohort study demonstrated how including additional plasma proteins significantly enhanced the performance of p-tau217 in predicting advanced tau pathology among amyloid-positive individuals, suggesting a multiprotein approach may offer a viable and scalable alternative to tau PET staging in clinical or resear...
Guglielmo di Molfetta, W. Brum, I. Pola et al.· JAMA Neurology· 1 citation
CSF p-tau205 as a biomarker of Alzheimer's disease pathology and progression with potential value for biological staging is supported and when incorporated into a conceptual CSF-based staging model, the final p-tau205-positive stage showed the strongest association with cortical atrophy, cognitive impairment, and risk...
J. Lantero-Rodríguez, S. Janelidze, S. Palmqvist et al.· Molecular Psychiatry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
